The medical technology firm raised its full-year earnings guidance after reporting $343.5 million in Q2 net sales and 6% organic growth.
CONMED Corporation updated its 2026 adjusted earnings per share forecast to a range of $4.48 to $4.60, up from prior expectations. The company targets 5% to 6% organic growth for the year.
In Q2 2026, CONMED reported net sales of $343.5 million, a 6% year-over-year increase in organic sales. Adjusted diluted EPS reached $1.38, boosted by a $0.21 benefit from tariff refunds not previously factored into estimates.
Management attributed the strong performance to operational execution and favorable market conditions, reinforcing confidence in the revised outlook.